Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 1Neoplasms, Germ Cell and Embryonal 1Nausea 1Glioma 1

Interventions

Etoposide 10Cisplatin 9Cyclophosphamide 7etoposide phosphate 5Paclitaxel 5Ifosfamide 5Granulocyte Colony-Stimulating Factor 5Carboplatin 5fludarabine 4Sirolimus 4Gemcitabine 4pembrolizumab 3fludarabine phosphate 3Sunitinib 3Mesna 3Melphalan 3Filgrastim 3Drug Therapy 3Brentuximab Vedotin 3Bleomycin 3Bevacizumab 3Automobiles 3tremelimumab 2sodium thiosulfate 2pegfilgrastim 2lutetium Lu 177 dotatate 2durvalumab 2Vorinostat 2Stem Cell Transplantation 2Oxaliplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasms, Germ Cell and Embryonal × rolapitant × Clear all
NCT03960151 2019-05-22

Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

Hoosier Cancer Research Network

Phase 2 Withdrawn

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡